[DOI] [PMC free article] [PubMed] [Google Scholar] [53].Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V
Introduction Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes (T2DM), with a relevant impact on the economic costs for health care systems and on the quality of life for many patients ( Among the novel therapies, great interest has been aroused by sodiumglucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), that have changed the management of diabetic patients
Ensure that the needle does not touch the flat surface or any of your fingers
Several reasons may explain slower-than-expected results
Dampened desire and the reward system
It may also end up being most useful for specific patient groups rather than everyone with diabetes or obesity